Sunflower Pharmaceutical GroupLtd's high ROE is impressive, likely driving its significant earnings growth. Despite retaining a small portion of profits, it has managed to increase earnings, a positive sign. The company's performance is quite pleasing overall.

Market expectations for growth seem moderated, with average annual share price increase of 26% lower than EPS growth. Positive sentiment around the company may hint at business momentum.

Harbin Pharmaceutical Group's low P/S ratio may indicate anticipated poor growth or falling revenue, underperforming the industry. The company's recent revenue trends, worse than industry expectations, contribute to its low P/S. Shareholders accept this, expecting no future revenue surprises. Unless medium-term conditions improve, they will continue to hinder the share price.

Market expectations of a decline in Henan Taloph Pharmaceutical's revenue performance and slower growth compared to the industry average may contribute to its low P/S ratio. Shareholders' wariness of the company's ability to keep up with industry growth could be a factor in the declining share price.

HPGC Renmintongtai Pharmaceutical Corporation's low P/E ratio may be due to anticipated significant degradation in earnings performance. The company's recent three-year growth being lower than market forecast also contributes to the low P/E. These trends may prevent a strong rise in share price soon.

Tasly Pharmaceutical Group's low P/E ratio may reflect limited future growth expectations. Shareholders accept this, acknowledging future earnings may not surprise positively. Unless conditions improve, this will continue to limit the share price.

Low P/S ratio suggests investors think company's growth may not keep up with the industry. Recent revenue trends imply the share price may not rise soon. Investors should beware of a specific warning for the company.

Heilongjiang ZBD Pharmaceutical's unstrained balance sheet may offset debt, but revenue decline and EBIT loss over last year highlight growth necessity. Still, liquid assets offer some cushion before debt becomes urgent. The company appears risky.

The share price growth exceeds EPS growth, suggesting the market values the company's growth history. The recent superior company performance, and ongoing share price momentum indicate potential investor opportunities.